Business Context and Reporting Period
Company: Trinity Biotech PLC
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 14, 2025
Context: The filing discloses a regulatory notice received from the Nasdaq Stock Market LLC regarding non-compliance with specific listing requirements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The material change reported is the receipt of a non-compliance notice from Nasdaq on March 14, 2025, citing two specific failures:
- Minimum Bid Price: The company failed to maintain a minimum bid price of US $1.00 per share for its American Depositary Shares (ADSs) over the last 30 consecutive business days (Nasdaq Listing Rule 5450(a)(1)).
- Market Value of Publicly Held Shares (MVPHS): The company failed to maintain a minimum MVPHS of US $15,000,000 over the last 30 consecutive business days (Nasdaq Listing Rule 5450(b)).
Outlook, Risks, and Management Commentary
Compliance Timeline: The company has been granted a period of 180 calendar days to regain compliance with the cited rules. The deadline to restore compliance is September 10, 2025.
Risk: Failure to regain compliance by the deadline could result in delisting from the Nasdaq Global Select Market.
Management Action: The company has issued a press release (Exhibit 99.1) detailing the notice and is now operating under the 180-day cure period.
Investor Verification Checklist
- Verify the current trading price of Trinity Biotech ADSs to assess the gap from the $1.00 minimum bid price requirement.
- Review the company's share count and public float to calculate the current Market Value of Publicly Held Shares against the $15 million threshold.
- Monitor future filings for a formal plan of action or corporate actions (e.g., reverse stock split) intended to restore compliance before September 10, 2025.
- Check for any subsequent press releases or 6-K filings regarding the status of the compliance review.